Anthropic announced the creation last week of its new Claude Science tool, which aims to help scientists conduct research and experiments faster. The company also said it will be using the tool to run drug programs itself. “We’ve decided to start running some drug programs ourselves,” Eric Kauderer-Abrams, head of life sciences at Anthropic, said, adding that the company is starting with a small number of early-stage, preclinical drug programs for neglected diseases, which he defined as those considered less attractive targets for the pharmaceutical and biotech industries because drugs to treat them would be less profitable. Kauderer-Abrams stated two primary objectives: “The first is accelerating scientific discovery as an end in itself, pure pursuit of basic research, and the second is accelerating, alleviating the burden of disease and aging.” By engaging in the research, Anthropic said the company can assess and evaluate its new Claude Science tool. A spokesman for Anthropic told WTOP the company could not yet provide specifics about its research since it was in the early stages.